Teprotumumab-related hyperglycemia.
Linus AmarikwaAbubakr MohamedSun H KimAndrea Lora KosslerChrysoula DosiouPublished in: The Journal of clinical endocrinology and metabolism (2022)
While effective, teprotumumab carries a significant risk of hyperglycemia, especially in patients with diabetes. Hyperglycemia may persist after stopping teprotumumab. These findings underscore the importance of guidelines for screening and management of teprotumumab-related hyperglycemia.
Keyphrases